Glaxo Consumer Has Time To Spread Wings Before Potential Solo Flight
This article was originally published in The Tan Sheet
GlaxoSmithKline will not consider spinning off of its consumer health business for two to three years, when it can evaluate its "full value," says CEO Andrew Witty. Sales of the OTC intranasal corticosteroid Flonase Allergy Relief led the firm's US consumer business sales in the latest quarter and throughout 2015.
Register for our free email digests: